John L. Lamattina - 27 Nov 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Andrew Reardon, Attorney-in-Fact For: For: John L. LaMattina
Issuer symbol
LGND
Transactions as of
27 Nov 2024
Net transactions value
-$171,668
Form type
4
Filing time
02 Dec 2024, 20:05:58 UTC
Previous filing
18 Jun 2024
Next filing
10 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $125,834 +2,406 +8.2% $52.30 31,921 27 Nov 2024 Direct
transaction LGND Common Stock Sale $297,502 -2,406 -7.5% $123.65 29,515 27 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,406 -100% $0.000000 0 27 Nov 2024 Common Stock 2,406 $52.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 2,754 shares on April 24, 2015, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.